Caplin Point Laboratories Limited · NSE:CAPLIPOINT
Caplin Point Laboratories — Q4 FY24 Earnings Presentation
20 slides from Caplin Point Laboratories's earnings presentation, May 2024
Slide 1: Earnings Presentation Q4 FY24
EARNINGS PRESENTATION Q4 FY24 Rated #1 in India for “Most Consistent Profitable Growth across the last 10 years” Second Largest wealth creator for the decade ending 2020* May 2024 www.caplinpoint.net #Value Research magazine – Wealth Insight June 2022 issue *The Economic Times
Slide 2: Disclaimer
Disclaimer The Presentation is to provide the general background information about the Company’s activities as at the date of the Presentation. The information contained herein is for general information purposes only and based on estimates and should not be considered as a recommendation that any i
Slide 3: Q4 FY24 Income Statement
Q4 FY24 Income Statement Revenue Gross Profit EBITDA 16% 23% 20% YoY YoY YoY 453 245 262 159 163 436 213 135 389 Q4 FY23 Q3 FY24 Q4 FY24 Q4 FY23 Q3 FY24 Q4 FY24 Q4 FY23 Q3 FY24 Q4 FY24 EBIT PAT Earnings Per Share 18% 20% YoY YoY 146 146 120 121 15.44 16.01 101 13.45 124 Q4 FY23 Q3 FY24 Q4 FY24 Q4 FY
Slide 4: Q4 FY24 Profit Margins
Q4 FY24 Profit Margins Gross Profit Margins (%) EBITDA Margins (%) 57.8% 35.2% 56.3% 34.5% 54.6% 33.8% Q4 FY23 Q3 FY24 Q4 FY24 Q4 FY23 Q3 FY24 Q4 FY24 EBIT Margins (%) PAT Margins (%) 32.2% 26.5% 25.8% 31.0% 31.1% 25.3% Q4 FY23 Q3 FY24 Q4 FY24 Q4 FY23 Q3 FY24 Q4 FY24 4
Slide 5: FY24 Income Statement
FY24 Income Statement Revenue Gross Profit EBITDA 16% 21% 24% YoY YoY YoY 1,694 618 970 497 1,467 804 FY23 FY24 FY23 FY24 FY23 FY24 EBIT PAT Profit Margins 25% 22% YoY YoY 54.8% 57.3% 565 461 452 377 35.1% 32.6% 29.7% 32.1% 24.8% 26.2% FY23 FY24 FY23 FY24 FY23 FY24 Gross Profit EBITDA EBIT PAT (All
Slide 6: FY24 Free Cash Reserves and other Key Metrics
FY24 Free Cash Reserves and other Key Metrics Free Cash Reserves Capital Investment Lifecycle 911 Cash Flow from 772 Operation: Rs. 318 Cr 694 194 470 146 284 91 223 77 73 65 126 47 49 46 68 101 26 26 27 8 Free Cashflow: Rs. 172 Cr FY 14 FY 15 FY 16 FY 17 FY 18 FY 19 FY 20 FY 21 FY 22 FY 23 FY 24 FY
Slide 7: Leadership Team
Leadership Team Chairman Perspectives Management Team Commenting on the recent performance, Mr. C.C. Paarthipan, Chairman of Caplin Dr. Sridhar Ganesan Mr. Vivek Partheeban Point Laboratories said: • Managing Director • Chief Operating Officer Caplin has delivered another remarkable year of consiste
Slide 8: Q4 FY24 Highlights (Emerging Markets)
Q4 FY24 Highlights (Emerging Markets) 01 02 03 04 Company has shortlisted 25 The company’s dominant Company draws up plans to Current breakup of revenue Softgel products to be filed in presence in Latin America enter niche segments of segments at LatAm: Mexico over the next 24 continues to drive str
Slide 9: Q4 FY24 Highlights (US and Regulated markets)
Q4 FY24 Highlights (US and Regulated markets) 01 02 03 04 Company receives three Company will launch 11 new products in the US in the Caplin Steriles USA Inc makes Company delivers robust and Ophthalmic product approvals current FY, in several niche quick progress with nearly 25 consistent growth in
Slide 10: Evolution Over the Decades
Evolution Over the Decades Commences Capex expansion in multiple Incorporates Caplin projects equaling INR 600 Work on Regulated Steriles USA Inc for Listed on Stock Started outsourcing from Started first commercial Cr. CRO wing Amaris Markets Injectable unit launching own label in US Exchange China
Slide 11: Research & Development Capabilities
Research & Development Capabilities 1 Caplin has 5 dedicated R&D setups (3 – DSIR approved and 2 under approval) R&D Expense (Rs. Crore) R&D Expense as a % of Operating Revenue 85 2 Continuous capex investment of over INR 721 Cr over last 8 years towards enhanced manufacturing and R&D capabilities,
Slide 12: Revenue Break up and Manufacturing Strategy
Revenue Break up and Manufacturing Strategy Revenue by Business Segment Revenue by Channel FY24 Operating Revenue (Emerging Markets) (Emerging Markets) 25% 18% 2% 75% 25% 55% 20% 80% Africa US LATAM Generic Branded Generic Wholesale Retail Institutional Caplin covers a wide spectrum of pharmaceutica
Slide 13: Generics and Branded Generics Product Mix
Generics and Branded Generics Product Mix Non-Steroidal Antiinflammatory Antihelminthics/ Dewormer Analgesic Drugs-NSAIDS Antibiotic and Antifungal Antihypertensive drug Electrolytes 13
Slide 14: Caplin Point Structure
Caplin Point Structure 100% Caplin Point Laboratories Subsidiary Caplin Steriles Ltd wholly Caplin Steriles USA Inc owned (BSE: 524742| NSE: CAPLIPOINT) (India) subsidiary (US) Manufacturing Units: Manufacturing Unit: Distribution: • CP I: Puducherry • CP IV: Gummidipoondi • Front-end trading arm fo
Slide 15: Manufacturing and R&D Platform
Manufacturing and R&D Platform Tamil Nadu, India Location of Plants and Facilities 11 10 2 4 1. Puducherry (CP I) 8 75 2. Gummidipoondi (CP II) 3 3. Chengalpattu (CP III) 1 4. Gummudipoondi (CP IV) 5. Chennai (CP V) CP I CP III 6. Hyderabad (CP VI) Puducherry Chengalpattu 7. Chennai (CP VII) 8. Chen
Slide 16: Strategic Investments
Strategic Investments Project Summary Facility Location Product Target Market Status Timeline CP1, Caplin Point Unit-I Suthukeny, Softgel Existing Markets Completed Q4 FY23 Puducherry CP4, Injectable Vials Caplin Steriles Gummidipoondi, and Pre-Filled Regulated Markets Completed Q4 FY24 Phase II Che
Slide 17: Caplin Point’s Investment Case
Caplin Point’s Investment Case Core Business to show consistent Caplin’s core business which is focused on Latin America and Francophone Africa is expected to grow at a growth steady pace with industry-average margins and benchmark cashflows Aspiration is to have exceptional compliance record and fo
Slide 18: Experienced and Visionary Board of Directors
Experienced and Visionary Board of Directors Mr. C.C. Paarthipan Dr. Sridhar Ganesan D Sathya Narayanan Dr. C K Gariyali, IAS Dr. R Nagendran Mr S Deenadayalan Chairman Managing Director Independent Director Independent Director Independent Director Independent Director 30+ Years of experience in 35
Slide 19: P&L for the Q4 FY24 – Consolidated
P&L for the Q4 FY24 – Consolidated Value (INR Cr) Q4 FY24 Q4 FY23 YoY (%) Q3 FY24 QoQ (%) FY24 FY23 YoY (%) Revenue from Operation 453.22 389.28 16.4% 435.50 4.1% 1,694.10 1,466.73 15.5% Other Income 17.29 11.40 17.18 66.94 55.98 Total Revenue 470.51 400.68 17.4% 452.68 3.9% 1,761.04 1,522.71 15.7%
Slide 20: Investor Relations at Caplin
INVESTOR RELATIONS AT CAPLIN Mr G Venkatram investors@caplinpoint.net CHURCHGATE PARTNERS Rajiv Pandya / Paresh Rohra caplinpoint@churchgatepartners.com 524742 CAPLIPOINT CIN: L24231TN1990PLC019053 ISIN: INE475E01026 |DUNS:86-148-4556 | WWW.CAPLINPOINT.NET ©2018, Caplin Point Laboratories Limited –
Caplin Point Laboratories — Q4 FY24 Earnings Presentation on 6ix